instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
This year’s National Health Interview Survey was the first to ask about sexual orientation in addition to health habits in its 57-year history, the U.S. Centers for Disease Control and Prevention said. Bisexual women were twice as likely to experience serious anxiety while bisexual men were more likely to indulge in binge drinking than others, according to the survey. In the survey of more than 34,500 Americans age 18 and above, 1.6 percent reported that they were gay and 0.7 percent reported that they were bisexual. A total of 96.6 percent reported being straight and 1.1 percent either said they were “something else,” did not know or declined to answer. Roughly twice as many women than men identified as bisexual, with 0.9 percent of female respondents saying they were attracted to both sexes. Bisexual women were twice as likely to report having serious anxiety than any other group, with almost 11 percent saying they had been distressed in the past month. Among bisexual men, almost 52 percent said they had five drinks or more in a night during the past year compared with only 31 percent of straight men. Gays and bisexuals fared as well or better than their straight peers in some areas, like exercising, taking HIV tests and receiving flu vaccines. “The differences went both ways, and it depends on the specific indicator that you were looking at,” said Brian Ward, a lead author on the survey and health statistician for the CDC’s statistical arm. The CDC said the survey findings were in line with other  research on health and sexual orientation, though a smaller proportion of people in this survey identified as bisexual than in other studies.
answer:
Government report finds 2.3 percent of Americans gay or bisexual.


question:
Maria Andrade of Cape Verde, Robert Mwanga of Uganda and American Jan Low, who all are from the Lima, Peru-based International Potato Center, and American Howarth Bouis of the international research group HarvestPlus were honored in a ceremony at the U.S. State Department. Kenneth M. Quinn, president of the World Food Prize Foundation, called their work “a breakthrough achievement in developing and implementing biofortification.”  He defined biofortification as “the process of breeding critical vitamins and micronutrients into staple crops, thereby dramatically reducing hidden hunger and improving health for millions and millions of people.”  The honorees’ work has focused on the orange-fleshed sweet potato, an important source of vitamin A, especially in sub-Saharan Africa. Vitamin A deficiency, especially there and in Asia, is a cause of blindness and premature death, according to the International Potato Center, an agriculture research center based in Lima, Peru. “The impact of the work of all four winners will be felt around the globe but particularly in sub-Saharan Africa,” said Gayle Smith, head of the U.S. Agency for International Development. The prize is awarded annually by the World Food Prize Foundation for food and agriculture innovation. The scientists will share the $250,000 prize equally and it will be awarded at a ceremony during World Food Prize week in Des Moines, Iowa, in October, when the prize will celebrate its 30th anniversary. Past recipients include John Kufuour, a former president of Ghana; former U.S. Senators Bob Dole and George McGovern; and Grameen Bank founder and Nobel laureate Dr. Muhammad Yunus of Bangladesh.
answer:
Sweet potato experts win World Food Prize.


question:
Low doses of the drug FTY720, also called fingolimod, given  to mice once a day for three days eliminated an infection by a  virus that can cause meningitis, an inflammation of the  membranes surrounding the brain and spinal cord. The findings suggest the drug, which boosted anti-viral  immune responses in the mice, may be useful against viruses  that cause high-level, long-lasting infections in people such  as hepatitis C and HIV, the researchers said. Microbiologist and immunologist John Altman of Emory  University in Atlanta, who led the study, said the researchers  plan to assess the effects of the drug on other viruses  including the monkey version of the AIDS virus. Altman, whose findings were published in the journal  Nature, expressed cautious optimism that the drug might work  against certain chronic viral infections in people. “We think it’s crucial that we do experiments to check it  out,” Altman said in a telephone interview. The drug is generally considered to be an immunosuppressant  that works to restrain the body’s natural defenses. That could be helpful in multiple sclerosis, an autoimmune  disease in which the immune system attacks body parts as if  they were foreign invaders. But one effect of the drug seems to facilitate the immune  response, the researchers said. FTY720 among other things traps  white blood cells — key soldiers in the immune system’s fight  against infections — in the lymph nodes, Altman said. With viral infections, the lymph nodes are where the immune  response can get primed and started, Altman said. Some viruses  replicate themselves at high levels in lymph nodes, including  the human immunodeficiency virus that causes AIDS. They tested the drug against a mouse virus called  lymphocytic choriomeningitis, which causes chronic infections  by escaping immune responses. “In the absence of treatment (with FTY720) we have an  exhausted immune response. In the presence of treatment, we  regain a robust cellular immune response,” Altman said. Swiss drug maker Novartis said in June two multiple  sclerosis patients taking FTY720 in clinical trials had  problems with infections and one died, but the role of the drug  in the cases was unclear. Novartis plans at the end of 2009 to seek approval by the  European Union for FTY720 to treat MS, spokeswoman Valerie Tate  said by e-mail. The drug is currently in late-stage trials. Altman said his study was backed by the U.S. government’s  National Institutes of Health and was not funded by Novartis.
answer:

MS drug may work against viral infection: study.